+44 (0)1509 263171
Please use this identifier to cite or link to this item:
|Title: ||Qualitative and quantitative demonstration of bead-to-bead transfer with bone marrow-derived human mesenchymal stem cells on microcarriers: utilising the phenomenon to improve culture performance|
|Authors: ||Rafiq, Qasim A.|
Hanga, Mariana P.
Heathman, Thomas R.J.
Nienow, Alvin W.
Williams, David J.
Hewitt, Christopher J.
|Keywords: ||Human mesenchymal stem cells|
Cell therapy bioprocessing
Bead to bead transfer
|Issue Date: ||2017|
|Publisher: ||© Elsevier|
|Citation: ||RAFIQ, Q.A. ... et al, 2017. Qualitative and quantitative demonstration of bead-to-bead transfer with bone marrow-derived human mesenchymal stem cells on microcarriers: utilising the phenomenon to improve culture performance. Biochemical Engineering Journal, doi: 10.1016/j.bej.2017.11.005.|
|Abstract: ||Human mesenchymal stem cells (hMSCs) are a key candidate for advanced cell therapies with numerous clinical trials investigating their potential to treat acute and chronic indications. However, important translational and manufacturing challenges need to be addressed to improve our capability for scalable production of fully functional cells. In this study, we have demonstrated, both qualitatively and quantitatively, the ability of bone marrow-derived hMSCs to migrate from one microcarrier to another, and, to populate fresh microcarriers when added into suspension culture. Additionally, we have shown that compared to inoculating a culture with cells in free suspension, inoculating 10% of near-confluent microcarriers from an initial seed microcarrier culture resulted in an increase in the cell growth rate and overall cell yield and a significant reduction in the lag phase. These findings were consistent across cells from three different BM-hMSC donors and across different culture medium conditions, foetal bovine serum-supplemented medium, human platelet lysate-supplemented medium and serum-free medium. This new cells-on-beads inoculation method is an effective means of process intensification with the potential to decrease manufacturing times and potentially costs of hMSC-based therapies.|
|Description: ||This paper is closed access until 15th November 2018.|
|Sponsor: ||This study has been funded by the Engineering and Physical Sciences Research Council via the E-TERM Landscape Fellowship programme (grant no. EP/I017801/1) and as part of the Doctoral Training Centre in Regenerative Medicine (grant no. EP/F500491/1), Bioprocessing Research Industry Club (BRIC) (grant No. BB/K011066/1 and BB/K01099/1) and Pall Life Sciences.|
|Version: ||Accepted for publication|
|Publisher Link: ||https://doi.org/10.1016/j.bej.2017.11.005|
|Appears in Collections:||Closed Access (Chemical Engineering)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.